| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 223,125 | 39,781 | ||
| Marketable securities | 168,548 | 185,125 | ||
| Prepaid expenses and other current assets | 5,829 | 4,284 | ||
| Total current assets | 397,502 | 229,190 | ||
| Total property and equipment | 2,614 | - | ||
| Less accumulated depreciation | 610 | - | ||
| Property and equipment, net | 2,004 | 1,730 | ||
| Right-of-use assets | 520 | 551 | ||
| Other assets | 50 | 50 | ||
| Total assets | 400,076 | 231,522 | ||
| Accounts payable | 3,768 | 5,764 | ||
| Accrued expenses | 8,140 | 5,854 | ||
| Operating lease liability, current | 154 | 138 | ||
| Total current liabilities | 12,062 | 11,756 | ||
| Share repurchase liability | 7 | 15 | ||
| Operating lease liability, net of current | 469 | 512 | ||
| Total liabilities | 12,538 | 12,283 | ||
| Common stock, 0.0001 par value, 500,000,000 shares authorized and 44,715,498 issued and outstanding as of september 30, 2025 and 500,000,000 shares authorized and 33,421,525 issued and outstanding as of december 31, 2024 | 6 | 5 | ||
| Additional paid-in-capital | 589,792 | 400,019 | ||
| Accumulated deficit | -202,414 | -180,796 | ||
| Accumulated other comprehensive income | 154 | 11 | ||
| Total stockholders' equity | 387,538 | 219,239 | ||
| Total liabilities and stockholders' equity | 400,076 | 231,522 | ||
MBX Biosciences, Inc. (MBX)
MBX Biosciences, Inc. (MBX)